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Abstract
Background: Cardiac contractility modulation (CCM) signals are non-excitatory electrical 
signals delivered during the absolute refractory period intended to improve contraction and car-
diac function. Clinical trials have shown that CCM treatment significantly improves exercise 
tolerance and quality of life in symptomatic heart failure patients. Studies with CCM therapy 
typically include CCM delivery for 3, 5 or 7 h per day, although other configurations are also 
commonly used. Each has been associated with improved outcomes in heart failure, but it is not 
clear whether different application durations are associated with the various degrees of benefit. 
The purpose of the current pilot evaluation study was to evaluate the quality of life, exercise 
tolerance, and cardiac function, over a 6-month period when CCM was delivered for 5 h/day 
vs. 12 h/day. Increasing the daily CCM therapy duration is safe and as good as the standard 
CCM periods of application per day.
Methods: This single center pilot evaluation study involved 19 medically refractory sympto-
matic patients with heart failure and reduced left ventricular function who underwent implan-
tation of an Optimizer™ system (Impulse Dynamics, Orangeburg, NY, USA). Patients were 
randomized into one of two treatment groups; 5 h/day CCM treatment or 12 h/day CCM treat-
ment. Subjects and evaluating physicians were blinded to the study group. Subjects returned 
to the hospital after 12 and 24 weeks. Efficacy evaluations included changes from baseline to 
24 weeks in Minnesota Living With Heart Failure Questionnaire score (MLWHFQ), maximal 
oxygen consumption in the cardio-pulmonary stress test (peak VO2), New York Heart Associa-
tion classification (NYHA), 6-min walk distance (6MWD), and ejection fraction (EF).
Results: At the end of 24 weeks, clinical improvement was observed in the entire cohort in all 
efficacy measures (mean change from baseline of –17.1 in MLWHFQ, –0.86 in NYHA, and 
improvement trend of 1.48 mL O2/kg/min in peak VO2, 31.3 m in 6MWD, and 2.25% in EF). 
There were no significant differences, either clinically or statistically, between the groups receiv-
ing CCM for 5 h/day vs. 12 h/day. Three subjects were voluntarily withdrawn before completing 
the study. One subject died from pneumonia after 125 days, and 6 serious adverse events were 
reported, none of which was classified as related to either the device or the procedure.
Conclusions: Together with previously reported experience with CCM, delivery of CCM  
therapy is equally safe and appears similarly effective over the range of shorter (5 h) to longer  
(12 h) daily periods of application. Given the small sample size, further studies are warranted. 
(Cardiol J 2016; 23, 1: 114–119)
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Introduction
Cardiac contractility modulation (CCM) is the 
application of non-excitatory electrical signals to 
the myocardium, during the absolute refractory 
period of the action potential, to augment contrac-
tion, and to promote reverse remodeling of heart 
failure (HF). This effect appears to contribute to 
long-term clinical benefit to HF patients, and is 
achieved without increasing myocardial oxygen 
consumption [1].
The bases for the effects of CCM have been 
reviewed recently [2]. The action of CCM appears 
to be mediated by molecular mechanisms that 
restore the ability of failing myocytes to more 
normally handle calcium cycling. This ameliorative 
action includes phosphorylation of cardiac phos-
pholamban which acutely improves the ability of 
the sarcoplasmic reticulum to sequester calcium. 
Chronically, CCM stimulates gene expression that 
restores production of proteins involved in calcium 
handling and contraction.
Following two pilot studies of chronic CCM 
signal application [3, 4] that demonstrated the 
device safety and functionality, larger scale studies 
were performed.
In a study of 428 patients with New York Heart 
Association (NYHA) class III or IV, narrow QRS HF 
(FIX-HF-5), CCM was found to be safe and showed 
an effect of improving quality of life and raising 
maximal oxygen consumption in cardio-pulmonary 
stress test (peak VO2) compared with the control 
group [5].
Subsequent analysis of patient subgroups 
revealed that CCM improves multiple objective 
parameters of exercise tolerance, including ventila-
tory anaerobic threshold, in a subgroup of patients 
characterized by normal QRS duration, NYHA 
functional class III symptoms, and ejection fraction 
(EF) of at least 25% [6].
Although previous studies have demonstrated 
the safety and efficacy of 3 h [4], 5 h [6] and 7 h [7] 
of CCM therapy per day, no direct comparison of 
the effects of different durations of CCM stimula-
tion have been reported.
The objective of this pilot evaluation study was 
to compare the impact of 6 months of 5 h vs. 12 h 
of CCM therapy per day on symptoms, quality of 
life and exercise tolerance in patients with medi-
cally refractory symptomatic HF and reduced left 
ventricular (LV) function.
Methods
Patients
This double blind active control study included 
19 patients. All procedures were approved by the 
local Ethics Committee and informed consent was 
obtained from all enrollees. Eligibility included: 
being above 18 years of age; stable use of optimal 
medical therapy for HF with doses and duration 
of treatment based on institutional standards of 
care; LVEF of 35% or less by echocardiography; 
and NYHA class III or IV symptoms.
The major exclusion criteria included: per-
manent atrial fibrillation, peak VO2 < 9 mL O2/ 
/kg/min, myocardial infarction within 3 months of 
enrollment, mechanical tricuspid or aortic valves, 
hospitalization for HF less than 2 weeks before en-
rollment and requiring the use of intravenous diuret-
ics or inotropic support; reduced exercise tolerance 
for reasons other than HF (e.g., angina, chronic 
obstructive pulmonary disease, peripheral vascular 
disease, orthopedic or rheumatologic conditions).
After obtaining informed consent, enrolled 
subjects were evaluated by echocardiography, 
cardiopulmonary stress testing, a 6-min walk 
distance (6MWD), HF questionnaire, and a 24-h 
Holter monitor.
Table 1 lists the baseline demographics and 
characteristics of participants. No statistical dif-
ference was apparent between the groups.
Study design
Following Optimizer implantation subjects 
were randomized to one of two treatment groups: 
group A (5 h/day CCM treatment) or group B 
(12 h/day CCM treatment), and the Optimizer pulse 
generator was programmed accordingly prior to 
hospital discharge. The CCM delivery schedule 
was programmed for multiple equally spaced 
stimuli of 1 h treatments.
Primary follow-up visits were performed at 
week 24 with interrogation of implanted devices 
(CCM, ICD). A medical history including NYHA 
classification and medications, physical examina-
tion, Minnesota Living Heart Failure Questionnaire 
(MLWHFQ) and 6MWD were obtained along with 
a cardiopulmonary stress test and echocardiogram.
Statistical methods
This study was a pilot evaluation of 5 h vs. 12 h 
of CCM per day, and was not powered to demon-
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strate statistical significance in safety or efficacy 
between groups, but to obtain initial assessment 
of trend, if any.
This was a randomized, double blind, active 
control study. Descriptive statistics are used to 
characterize baseline characteristics of the two ran-
domized groups. Differences in changes in efficacy 
parameters between baseline and 6 months were 
evaluated based on the two co-primary outcome 
measures of the mean change in the MLWHFQ 
score and the mean change in exercise tolerance, 
as measured by peak VO2 determined during car-
diopulmonary exercise stress testing. The results 
were analyzed by calculating the mean change for 
each parameter, and the overall level of significance 
used for this exploratory, feasibility study was 0.05, 
calculated by a 2-sample t-test comparing the 
5 vs. 12 CCM hour groups.
Serious adverse events (SAEs) were reported 
and reviewed for clinical significance.
Results
Each MLWHFQ, NYHA, peak VO2 and 6MWD 
co-primary endpoint shows clinical improvement 
or a trend toward clinical benefit at 24 weeks vs. 
baseline in patients receiving either 5 h/day of 
CCM or those receiving 12 h/day stimulation. In 
the 5 h/day stimulation group, MLWHFQ showed 
trend to decrease by 18.5 ± 26.1; peak VO2 showed 
trend to increase by 0.82 ± 2.81 mL/kg/min; and 
NYHA decreased by 0.88 ± 0.83 (p = 0.02). Simi-
larly, in the 12 h/day stimulation group, MLWHFQ 
showed trend to decrease by 15.2 ± 16.9; peak VO2 
showed trend to increase by 2.3 ± 1.6 mL/kg/min; 
and NYHA decreased by 0.83 ± 0.75 (p = 0.04) 
(Table 2). 6MWD showed similar trend to increase 
by 32 m and 29 m (p = NS), and there were too 
little data to determine meaningful changes in EF. 
There were no significant differences in any of the 
efficacy measures when comparing the 5 and the 
Table 1. Baseline demographics and characteristics. No statistical difference was apparent between 
the groups.
5 h group 12 h group All
N 9 10 19
Age 62.4 ± 9.2 63.7 ± 9.6 63.1 ± 9.2
Gender:
Male 9 9 (90%) 18 (94.7%)
Female 0 1 (10%) 1 (5.3%)
Cardiomyopathy:
Ischemic 5 (55.6%) 3 (30%) 8 (42.1%)
Dilated 4 (44.4%) 7 (70%) 11 (57.9%)
History:
Myocardial infarction 4 (44.4%) 3 (30%) 7 (36.8%)
CABG 2 (22.2%) 3 (30%) 5 (26.3%)
PCI 4 (44.4%) 5 (50%) 9 (47.4%)
Angina 0 0 0
NYHA score 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0
MLWHFQ 52 ± 20 47 ± 15 49 ± 17
6MWD 324 ± 128 (n = 9) 333 ± 107 (n = 9) 328 ± 115 (n = 18)
Peak VO2 [mL/kg/min] 11.8 ± 2.1 11.8 ± 2.0 11.8 ± 2.0
Ejection fraction 27 ± 8 30 ± 5 29 ± 6
LVEDD 65 ± 10 59 ± 11 62 ± 11
Medications:
Beta-blockers 7 (77.8%) 7 (70%) 14 (73.7%)
ACE-I 6 (66.7%) 6 (65%) 12 (66.1%)
Diuretic 7 (77.8%) 8 (80%) 15 (78.9%)
CABG — coronary artery bypass graft; PCI — percutaneous coronary intervention; NYHA — New York Heart Association classification;  
MLWHFQ — Minnesota Living With Heart Failure Questionnaire; 6MWD — 6-min walking distance; peak VO2 — maximal oxygen consumption 
in cardio-pulmonary stress test; LVEDD — left ventricular end diastolic dimension; ACE-I — angiotensin-converting-enzyme inhibitor
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12 CCM hours/day groups. Furthermore, in this 
small cohort, no consistent trends among any ef-
ficacy measures were shown to clearly differentiate 
5 h/day or 12 h/day stimulation groups.
Combining the two study groups revealed an 
improvement from baseline in two clinical parame-
ters. MLWHFQ improved by –17.1 ± 21.9 (p = 0.01) 
and NYHA improved by –0.86 ± 0.77 (p < 0.01). 
Furthermore, trends toward an improvement were 
observed with peak VO2 (by 1.48 ± 2.35), 6MWD 
(by 31.3 ± 101.3), and EF (by 2.3 ± 7.0). The clini-
cal improvement vs. baseline was of similar mag-
nitude to that described previously using 5 h/day 
and 7 h/day of CCM [6–8].
Three subjects were voluntarily withdrawn 
prior to completing the study for non-medical 
reasons, and a total of 6 SAEs were reported, none 
of which was related to either the device or the 
procedure.
A total of 9 adeverse events were reported 
in 5 subjects during the study. Of those, 6 were 
SAEs, reported in 3 subjects, including one death 
of a subject from pneumonia 125 days post-implant. 
This death was classified by the investigator as not 
related to the device or to the procedure. Table 3 
summarizes the SAEs. No adverse events were 
classified by the investigator as related to either 
the device or the procedure. The reported adverse 
events are typical of patients with similar degrees 
of HF. Two patients with SAE were in the 12 h/day 
group and 1 patient was in the 5 h/day group.
There were no device deficiencies reported 
and blinding by subjects and investigators was 
maintained throughout the study.
Discussion
The major finding of this study is that both 5 h/ 
/day and 12 h/day of CCM are similarly beneficial in 
terms of quality of life measures and cardiovascular 
functional improvement at 24 weeks. Furthermore, 
in this direct comparison between different dura-
tions of CCM stimulation, no difference in adverse 
events was seen. These findings support use of 
patient-specific programming of duration of CCM 
stimulation. The experience from past studies and 
in routine experience (using 3–7 h/day and beyond) 
combined with the data from this study suggest that 
any number of CCM h/day in the range of 5 h to 12 h 
may be considered safe and similarly effective, and 
therefore the physician can apply judgment about 
tuning the CCM delivery hours per day to each 
individual patient.
Table 2. Efficacy data.
MLWHFQ Peak VO2  
[mL O2/kg/min]
NYHA 6MWD 
[m]
EF  
[%]
5 CCM h/day
Baseline to 24 weeks difference Mean –18.50 0.82 –0.88 32.43 –1.25
SD 26.09 2.81 0.83 130.03 8.54
N 8 5 8 7 4
12 CCM h/day
Baseline to 24 weeks difference Mean –15.17 2.30 –0.83 29.60 5.75
SD 16.94 1.61 0.75 53.49 2.99
N 6 4 6 5 4
Difference between groups 3.33 1.48 0.04 –2.83 7.00
P 0.78 0.36 0.92 0.96 0.20
MLWHFQ — Minnesota Living With Heart Failure Questionnaire; peak VO2 — maximal oxygen consumption in cardio-pulmonary stress test; 
NYHA — New York Heart Association classification; 6MWD — 6-min walking distance; EF — ejection fraction; SD — standard deviation
Table 3. Summary of reported serious adverse 
events.
Category of event No. of  
events
No.of  
patients 
Worsening HF 1 1
Progression of CAD 1 1
Arrhythmias (VT, atypical AF) 2 2
Pneumonia (later leading  
to death)
1 1
Angina pectoris 1 1
Total 6 3
HF — heart failure; CAD — coronary artery disease; VT — ventricu-
lar tachycardia; AF — atrial fibrillation
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A very important example of when such tuning 
of CCM delivery hours per day per patient could be 
useful is in patients with frequent ectopy. In these 
cases, the ectopic beats inhibit CCM delivery by 
the current Optimizer™ device and may reduce 
the overall CCM delivery duration. Increasing 
the average “ON” time per day may compensate 
for reduced therapy due to beats where CCM was 
inhibited, and therefore achieves similar overall 
duration of CCM stimulation as in the absence of 
ectopy. As experience continues to increase with 
CCM, it will be of interest to find other subgroups 
of patients who would benefit from changes in 
duration of CCM delivery [9].
Despite receiving recommended medical 
treatment, a significant number of chronic HF 
patients remain symptomatic. Nearly 50% of pa-
tients meet the criteria for cardiac resynchroniza-
tion therapy and of these, as many as 30–50% are 
non-responders. Additional treatment modalities 
known to be clinically effective, such as CCM, may 
be helpful in these circumstances [10, 11].
Within the framework of the small amount 
of available data, patients appear to experience 
improvement in their clinical condition, and no 
note-worthy deterioration in the state of health of 
subjects was seen in either the 5 h/day CCM group 
or the 12 h/day CCM/group. While no statistical dif-
ferences were observed between CCM stimulation 
duration, and together with previously reported 
studies with CCM therapy, the data suggest that 
a broad range of daily stimulation durations may 
be considered safe and effective for CCM therapy.
The safety and efficacy of CCM therapy in HF 
patients has been shown in a number of studies 
[1, 5, 7, 8, 12]. Current evidence indicates that the 
mechanism of action relates to beneficial modula-
tion of gene expression and protein expression 
within a few hours of activation [13, 14]. This 
supports the intermittent application regimen, 
which also extends battery life. Results of this 
study showing similar efficacy to prior published 
work suggest that 5 h of stimulation per day is suf-
ficient for activating the longer-term genetic and 
protein remodeling benefit of CCM, and with that to 
a sustained clinical benefit [15].
Limitations of the study
This study was not powered to detect a small 
or modest difference between the 5 h and 12 h 
CCM delivery. However, such a difference is not 
likely to be present, given the similarity between 
groups among each of the measured parameters. 
In fact, the primary and most secondary measures 
improved similarly with both durations of stimula-
tion (5 h and 12 h) indicating that either duration 
exceeds the threshold for efficacy. It is not clear 
whether continued increases in duration of CCM 
delivery would be associated with a further im-
provement in efficacy.
All but one subject enrolled was male and there 
were no minority subjects. Recruitment of women 
and minorities is needed to provide a broader 
diversity-enriched cohort of subjects.
Large absolute differences between 5 h and 
12 h of stimulation were observed with the assess-
ment of cardiac function (EF). Due to the small 
sample size and the typical standard deviations in 
this type of measurement this was not statistically 
significant. Future studies should examine these 
endpoints in detail using a larger number of patients.
Conclusions
In this small cohort, previously reported 
safety and efficacy of the CCM therapy are equally 
achieved using duration of CCM delivery of either 
5 h/day or 12 h/day. These data support the availa-
bility of a broader range of CCM delivery durations 
for optimizing CCM delivery to patients with HF 
and reduced EF, expanding opportunities to improve 
cardiac function and clinical status in patients with 
moderate to severe HF.
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